Bogle Investment Management’s ANI Pharmaceuticals ANIP Stock Holding History

Bogle Investment Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-42,700	Closed	-$2.49M	–	280
2018 Q1	$2.49M	Buy	+42,700	New	+$2.71M	0.19%	138
2016 Q4	–	Sell	-55,705	Closed	-$3.7M	–	329
2016 Q3	$3.7M	Buy	+55,705	New	+$3.48M	0.27%	123
2015 Q2	–	Sell	-184,213	Closed	-$11.5M	–	352
2015 Q1	$11.5M	Sell	184,213 -9,915	-5%	-$603K	0.79%	33
2014 Q4	$10.9M	Buy	+194,128	New	+$8.56M	0.73%	48

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bogle Investment Management's ANIP Position: Q2 2018 in Review

Bogle Investment Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2018, closing a stake of 42,700 shares — an estimated $2.49M sold.

Bogle Investment Management first reported a position in ANIP in Q4 2014 and held it in 4 quarters. The position peaked at $11.5M in Q1 2015. 184 funds tracked by Wall St. Rank hold ANIP as of Q2 2018.

Bogle Investment Management reported no remaining ANI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Bogle Investment Management sold 42,700 ANI Pharmaceuticals shares in Q2 2018, an estimated $2.49M.
Bogle Investment Management first reported a position in ANI Pharmaceuticals in Q4 2014 and held it in 4 quarters.
Bogle Investment Management's ANI Pharmaceuticals position peaked at $11.5M in Q1 2015.
184 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2018.

Based on Bogle Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.